149 related articles for article (PubMed ID: 25312592)
1. Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery.
Bringeland EA; Wasmuth HH; Fougner R; Mjønes P; Grønbech JE
Br J Surg; 2014 Dec; 101(13):1712-20. PubMed ID: 25312592
[TBL] [Abstract][Full Text] [Related]
2. Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit.
Hølmebakk T; Frykholm G; Viste A;
Eur J Surg Oncol; 2010 Jul; 36(7):610-6. PubMed ID: 20627647
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
4. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.
Persiani R; Rausei S; Pozzo C; Biondi A; Barone C; Cananzi FC; Schinzari G; D'Ugo D
Ann Surg Oncol; 2008 Aug; 15(8):2146-52. PubMed ID: 18543037
[TBL] [Abstract][Full Text] [Related]
5. Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer.
Koppert LB; Lemmens VE; Coebergh JW; Steyerberg EW; Wijnhoven BP; Tilanus HW; Janssen-Heijnen ML
Br J Surg; 2012 Dec; 99(12):1693-700. PubMed ID: 23132417
[TBL] [Abstract][Full Text] [Related]
6. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
Shi C; Yang B; Chen Q; Yang J; Fan N
Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768
[TBL] [Abstract][Full Text] [Related]
11. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
12. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Zhang Q; Tey J; Peng L; Yang Z; Xiong F; Jiang R; Liu T; Fu S; Lu JJ
Radiother Oncol; 2012 Jan; 102(1):51-5. PubMed ID: 22178689
[TBL] [Abstract][Full Text] [Related]
14. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
Findlay M; Storey D; Gebski V; Hargreaves C; Cullingford G; Boyer M; Trotter J; Archer S; Davidson A; Johnston P; Yuen J; Dhillon H; Della-Fiorentina S; Richardson G; Truskett P; Goldstein D;
ANZ J Surg; 2007 Apr; 77(4):247-52. PubMed ID: 17388828
[TBL] [Abstract][Full Text] [Related]
16. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance.
An JY; Kim KM; Kim YM; Cheong JH; Hyung WJ; Noh SH
Ann Surg Oncol; 2012 Aug; 19(8):2452-8. PubMed ID: 22395984
[TBL] [Abstract][Full Text] [Related]
17. Results of immunochemo-surgery for gastric carcinoma.
Kim JP; Yu HJ; Lee JH
Hepatogastroenterology; 2001; 48(41):1227-30. PubMed ID: 11677936
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
Iwasaki Y; Sasako M; Yamamoto S; Nakamura K; Sano T; Katai H; Tsujinaka T; Nashimoto A; Fukushima N; Tsuburaya A;
J Surg Oncol; 2013 Jun; 107(7):741-5. PubMed ID: 23400787
[TBL] [Abstract][Full Text] [Related]
19. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
